

	technology	grant amount EUR
Vaccines - rough estimation of commitments		
AstraZeneca (contract concluded)	Non-replication viral vector	5.1.2b
BioNTech/Pfizer (tender is about to start)	mRNA	
Curevac (tender is opened)	mRNA	
Moderna (tender is opened)	mRNA	
Novavax (exploratory talks continue)	Protein subunit	
J&J (tender is opened)	Non-replication viral vector	
Sanofi (tender is running)	Protein subunit	
Total Vaccines		

Total Price/Dose	Price/Dose (upfront payment subtracted)	Earliest delivery date	Total Number of Doses
5.1.2b	EUR	EUR Q4 '20 (30-40 Mio. doses)	300 Mio.
	EUR	EUR Q4 '20 (25 Mio. doses)	200 Mio.
	EUR	EUR Q1 '21 (50 Mio. doses)	225 Mio.
5.1.2b	USD	USD Q1 '21 (10 Mio. doses)	80 Mio.
	USD	USD Q1 '21 (21 Mio. doses)	100 Mio.
	USD	USD Q2 '21 (55 Mio. doses)	200 Mio.
	EUR	EUR Q3 '21 (150 Mio. doses)	300 Mio.
			1,45 Mrd.